Ana Ward
molecular biology , LAW
OVID THERAPEUTICS
New Zealand
Biography
Ana Ward, Esq., MS2, MBA, joined Ovid Therapeutics as Senior Vice President & General counsel in September of 2017. Ana previously served as General Counsel, Executive Vice President Patient Access & Corporate Development, and Board Secretary of Rosetta Genomics, Ltd., overseeing public company reporting and executing licensing and partnership activities. Prior to Rosetta Genomics, Ana held a series of leadership roles within the Ambion family of companies, including Ambion, Inc. (acquired by Applied Biosystems), Asuragen, Inc. (a spin-off of Ambion, Inc.) and Mirna Therapeutics, Inc. (a spin-off of Asuragen, Inc.), where she was responsible for managing a diverse portfolio of legal matters such as intellectual property claims, compliance, trademark clearance, and strategic business interactions. Ana holds a bachelor of arts in French, a master of science in molecular biology and a masters of business administration, all from the University of Texas, Austin, and a juris doctorate from the University of Texas Law School. Ana also holds a master of science in bioscience regulatory affairs from Johns Hopkins University.
Research Interest
-
